Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2

Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are validated molecular targets in cancer therapy. Dual blockade has been explored and one such agent, lapatinib, is in clinical practice but with modest activity. Through chemical screening, we discovered a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Sci
Egile Nagusiak: Tanaka, Hidekazu, Hirata, Michinari, Shinonome, Satomi, Wada, Toru, Iguchi, Motofumi, Dohi, Keiji, Inoue, Makiko, Ishioka, Yukichi, Hojo, Kanji, Yamada, Tomomi, Sugimoto, Tatsuya, Masuno, Koichi, Nezasa, Ken-ichi, Sato, Norihito, Matsuo, Kenji, Yonezawa, Shuji, Frenkel, Eugene P, Shichijo, Michitaka
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Blackwell Publishing Ltd 2014
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4317859/
https://ncbi.nlm.nih.gov/pubmed/24837299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12449
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak